Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers highlights increased cholesterol awareness as benefit of Questran switch.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL HIGHLIGHTS CHOLESTEROL EDUCATION RESULTING FROM QUESTRAN SWITCH in making its case for approval of the switch application during a joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees on Sept. 27. "We need to focus more educational effort on the professional as well as the consumer, and the over-the-counter product availability is going to make that possible," Virgil Brown, MD, Emory University School of Medicine, said in a presentation to the committee on behalf of Bristol-Myers Squibb.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts